Efficacy and safety of interleukin‐17 inhibitors for psoriasis

Real‐world efficacy and safety of interleukin‐17 inhibitors for psoriasis: A single‐center experience:

Abstract

We evaluated the efficacy and safety of interleukin (IL)‐17 inhibitors (IL‐17i) by analyzing 66 patients with psoriasis treated with secukinumab (n = 25), ixekizumab (n = 17) and brodalumab (n = 24) at Kurume University Hospital between December 2014 and June 2019. The mean Psoriasis Area and Severity Index (PASI) scores at baseline were 12.9, 13.4 and 9.9 in the secukinumab, ixekizumab and brodalumab groups (SECg, IXEg and BROg), respectively. At the 6‐month evaluation, the mean PASI scores were 1.7, 1.1 and 0.5 in SECg, IXEg and BROg, respectively. The proportion of patients achieving PASI of 3.0 or less was significantly lower in SECg. Drug survivals showed no significant difference among the groups. Although one patient in IXEg died due to an unknown cause, no serious IL‐17i‐associated adverse event was observed. This study showed high efficacy and relatively low risk of the treatment with IL‐17i.